预约演示
更新于：2024-12-27
Novexatin
更新于：2024-12-27
概要
基本信息
原研机构 |
在研机构- |
最高研发阶段无进展临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H84N28O7 |
InChIKeyNVZLKNHDHPPJHL-RMIXPHLWSA-N |
CAS号942577-31-3 |
Sequence Code 6951
关联
2
项与 Novexatin 相关的临床试验NCT02933879
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability Patients With Mild to Moderate Onychomycosis
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8-Week Regimens of NVXT topical product in Patients with Mild to Moderate Onychomycosis
开始日期2016-03-21 |
NCT02343627
A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Assess the Safety and Efficacy of NVXT Solution in Patients With Mild-to-Moderate Fungal Infection of the Toe Nail
This study will examine the safety, tolerability and efficacy of NVXT in a new formulation in patients with mild-to-moderate fungal infection of the toe nail.
开始日期2014-12-01 |
100 项与 Novexatin 相关的临床结果
登录后查看更多信息
100 项与 Novexatin 相关的转化医学
登录后查看更多信息
100 项与 Novexatin 相关的专利（医药）
登录后查看更多信息
6
项与 Novexatin 相关的文献（医药）2023-08-02·Medical mycology
Correction to: NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile.
2022-05-01·Journal of drugs in dermatology : JDD4区 · 医学
Future Fungal Fighters in Dermatology: Novel Antifungal Drug Pipeline
4区 · 医学
Review
作者: Rosen, Theodore ; Khalfe, Yasmin
Over the last decade, major advances in antifungal drug development have occurred. Novel drugs in the pipeline include ME1111, MAT2203, rezafungin, ibrexafungerp, olorofim, fosmanogepix, MGCD290, VT-1161, NP213, T-2307, aureobasidin A, and nikkomycin Z. While most of these “future fungal fighters” have been developed to address invasive fungal infections (IFI), there is potential for dermatologists to benefit as these drugs may be adapted for superficial infections. Here, we review the major developments in novel antifungals and examine the ways in which dermatologists may gain from these recent innovations. J Drugs Dermatol. 2022;21(5):496-501. doi:10.36849/JDD.6373.
2020-11-10·Medical mycology3区 · 医学
NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile
3区 · 医学
Article
作者: O'Neil, Deborah A ; Robertson, Jennifer C ; Stewart, Colin S ; Miller, Lorna ; Mercer, Derry K
Abstract:
NP213 (Novexatin®) is a novel antifungal peptide specifically designed for the topical treatment of onychomycosis. NP213 was designed using host defense peptides (HDP), essential components of the innate immune response to infection, as a template. NP213 is a water-soluble cyclic fungicidal peptide that effectively penetrates human nail. NP213 demonstrated a promising preclinical and clinical safety profile, with no evidence of systemic exposure following topical application to the skin and nails. NP213 was efficacious in two phase IIa human trials with 43.3% of patients having no fungi detectable by culture of fragments from NP213-treated nails after 180 days in the first study and likewise 56.5% of patients were culture negative for dermatophytes after 360 days in the second phase IIa study. In both trials, NP213 was applied daily for only 28 days in marked contrast to other topical onychomycosis treatments that require application for up to 52 weeks. Patient reported outcomes from the phase IIa studies were positive with participants recording an improved appearance of their nails after only 14 days of application. All fungi identified in these studies were Trichophyton spp. NP213 (Novexatin®) is a promising, highly differentiated peptide-based candidate for the topical treatment of onychomycosis, addressing the infectious cause and cosmetic issues of this very common condition.
1
项与 Novexatin 相关的新闻（医药）2015-09-10
Recently added to the BioPortfolio report store,
Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015 is a new report from
Global Markets Direct published on 2015-07-30.
This 68-page report
is available in PDF
from $2000.
Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015’, provides an overview of the Onychomycosis (Tinea Unguium)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Onychomycosis (Tinea Unguium) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Onychomycosis (Tinea Unguium) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
…
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Onychomycosis (Tinea Unguium) Overview 8
Therapeutics Development 9
Pipeline Products for Onychomycosis (Tinea Unguium) - Overview 9
Pipeline Products for Onychomycosis (Tinea Unguium) - Comparative Analysis 10
Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies 11
Onychomycosis (Tinea Unguium) - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Onychomycosis (Tinea Unguium) - Products under Development by Companies 15
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development 16
Anacor Pharmaceuticals, Inc. 16
Eisai Co., Ltd. 17
Helix BioMedix, Inc. 18
Hexima Limited 19
Meiji Seika Pharma Co., Ltd. 20
Moberg Pharma AB 21
NAL Pharmaceuticals Ltd. 22
Nihon Nohyaku Co., Ltd. 23
Novabiotics Limited 24
Nuvo Research Inc. 25
Viamet Pharmaceuticals, Inc. 26
Onychomycosis (Tinea Unguium) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
AN-2718 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
E-1224 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ELS-160 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
HB-1275 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
HXP-124 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
luliconazole - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ME-1111 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
NAL-3216 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NP-213 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
terbinafine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
terbinafine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
VT-1161 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Onychomycosis (Tinea Unguium) - Recent Pipeline Updates 53
Onychomycosis (Tinea Unguium) - Dormant Projects 58
Onychomycosis (Tinea Unguium) - Discontinued Products 61
Onychomycosis (Tinea Unguium) - Product Development Milestones 62
Featured News & Press Releases 62
Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical…
For more information open Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015.
SKU: GMDHC6868IDB
First in Class
100 项与 Novexatin 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 甲癣 | 临床2期 | 英国 | 2009-09-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | - | 夢糧餘顧範糧遞顧築願(餘醖願憲遞襯願構鑰遞) = 選鏇願夢醖糧獵膚糧鬱 鬱餘蓋廠壓艱構繭築艱 (齋餘壓觸簾築構壓遞願 ) 更多 | 积极 | 2020-11-10 | |||
临床2期 | 184 | (NVXT Topical Treatment Group A) | 窪鑰鑰憲鏇醖願築製獵(鹽鑰繭壓簾艱願鬱鏇鏇) = 獵衊觸鏇夢廠繭齋齋選 製製鬱獵憲鏇壓糧廠壓 (蓋繭蓋顧鏇醖鑰壓願顧, 糧鬱築鹹鑰艱廠選築壓 ~ 網淵醖鑰窪遞衊淵淵鑰) 更多 | - | 2018-12-20 | ||
(NVXT Topical Treatment Group B) | 窪鑰鑰憲鏇醖願築製獵(鹽鑰繭壓簾艱願鬱鏇鏇) = 糧醖夢衊積簾鏇鬱齋衊 製製鬱獵憲鏇壓糧廠壓 (蓋繭蓋顧鏇醖鑰壓願顧, 膚鑰觸鬱願鑰窪網蓋襯 ~ 願製窪窪鬱鹽膚醖積衊) 更多 | ||||||
临床2期 | 47 | (NVXT Solution) | 鹹構鏇鏇鹹襯餘鑰鑰積(網網築窪遞鑰齋築顧選) = 膚願襯簾鏇齋構鏇糧選 膚積齋選醖窪鏇鹹繭衊 (構壓餘積蓋鏇築艱膚製, 鹽製鬱簾餘蓋觸鬱蓋糧 ~ 觸壓顧艱壓網齋廠繭範) 更多 | - | 2018-08-22 | ||
Vehicle of test product (Vehicle of Test Product) | 鹹構鏇鏇鹹襯餘鑰鑰積(網網築窪遞鑰齋築顧選) = 糧製鬱範憲艱繭鹽範鬱 膚積齋選醖窪鏇鹹繭衊 (構壓餘積蓋鏇築艱膚製, 範繭鏇構遞築壓淵廠淵 ~ 網膚夢選淵齋範觸窪膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用